BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:EVM14 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of EVM14\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07614646-2479@assetmemo.bio
DTSTAMP:20261121T005328Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:EVM14: Phase 1 readout est. (NCT07614646)
DESCRIPTION:EVM14\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Evaluate 
 the Safety\, Tolerability\, and Preliminary Efficacy of EVM14 in Combinati
 on With Ivonescimab in Sq-NSCLC Patients\nEstimated primary completion: Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/evm14#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07614646
URL:https://assetmemo.bio/drug/evm14#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07095868-2479@assetmemo.bio
DTSTAMP:20261121T005328Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:EVM14: Phase 1/2 readout est. (NCT07095868)
DESCRIPTION:EVM14\, phase 1/2.\nStudy: Evaluate the Safety\, Tolerability\,
  and Preliminary Efficacy of EVM14 Alone and in Combination in Patients Wi
 th Selected Solid Tumors\nEstimated primary completion: November 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/evm14#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07095868
URL:https://assetmemo.bio/drug/evm14#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
